Strand and Pharmidex to collaborate to produce a new in silico technology for CNS drug discovery
23 Feb 2006 -
Strand Life Sciences announced that it has entered into a collaboration with Pharmidex. Both companies focus on providing solutions to facilitate the discovery and development of new medicines. Under the collaborative agreement both Strand and Pharmidex will promote each others existing offerings and will jointly develop new software to predict the ability of compounds to cross the blood-brain barrier
(BBB). This effectively combines the in silico expertise of Strand with the BBB-focused offering of Pharmidex, which includes in vitro, ex vivo and in vivo methodologies.
Additional information
Pharmidex Pharmaceutical Services Ltd London, United Kingdom
Top
Contact
Print version
PDF version
Send article
RSS feed
